Abstrakt
We analyzed the impact of immunoglobulin M (IgM) positivity on relapse-free interval post completed course of cyclophosphamide (CYC) treatment in patients with steroid-dependent nephrotic syndrome (SDNS) and minimal change disease (MCD). Based on our results, we conclude that more than 50% of our SDNS patients with MCD remained relapse-free 4 years post-CYC treatment.
No significant difference in the response to CYC was observed between patients with or without IgM positivity.